Real-World Evidence (RWE) – Turning Routine Healthcare Data into Findings
Contents
What is real-world evidence?
Real-world evidence, or RWE, is clinical evidence generated through analysis of real-world data. Relevant sources may include health records, registries and healthcare claims. A data source alone is not evidence; a suitable question and analysis are needed to support a conclusion.
RWE is not automatically synonymous with one study design. Routine healthcare information may be used in different types of investigation. The key consideration is whether the method can address the particular question appropriately.
Why does RWE matter to pharmaceutical companies?
Routine-care information can illuminate questions that controlled authorization studies cover only partly. Examples include care pathways, use in particular populations and longer-term observations. Suitability for regulatory or reimbursement purposes needs assessment in the relevant context.
Such findings can add perspective to communication, but should not automatically be presented as proof of superior efficacy. The strength and scope of the conclusion depend on the design, information quality and potential sources of bias.
How should an RWE investigation be planned?
Reliable planning starts with the scientific question rather than an existing large dataset.
- Define the question: Specify the population, treatment, comparison and relevant outcomes.
- Assess the source: Examine coverage, completeness, measurement quality and permitted use.
- Choose the method: Address selection processes, confounding and missing information systematically.
- Report findings: Present assumptions, uncertainty and limitations alongside the results.
A prespecified analysis plan improves traceability and reduces opportunities to select favorable findings after inspecting the results. The plan should make clear which conclusions the available information can reasonably support.
What limitations affect interpretation?
In non-randomized analyses, treatment groups may differ before treatment begins. Other factors can therefore influence an observed association. A large sample does not automatically remove these systematic problems.
Privacy requirements and information provenance also need to be established. Pseudonymized health records may remain personal data. Marketing teams should interpret studies with medical and methodological specialists and avoid extending claims beyond the relationship actually investigated. Observation should not be described as proof of causation without an appropriate basis.
Why treatment groups may differ before treatment
In an explicitly simplified example, a treatment is mainly used by people with more severe disease. More subsequent hospital admissions in their routine records do not directly establish that treatment caused harm. Baseline severity may influence the comparison. Appropriate analyses address such differences, but unknown or unrecorded factors may remain. More records alone do not solve the problem.
Conclusion: Routine data requires an appropriate method
RWE can extend understanding of healthcare delivery. Its value depends on a precise question, suitable information and a defensible analysis. Pharmaceutical communication should describe opportunities and limitations with equal care and avoid overstating the certainty of observational findings.
